Biotechs Going It Alone Must Build Global Regulatory Plans From Day One
Start here
With the funding environment rebounding, more biotech companies are choosing to commercialize their products independently rather than partner with larger pharma firms. That path now demands a global regulatory strategy built into development from the start, with parallel submissions to multiple regulators planned early rather than sequential filings. The FDA remains the anchor regulator, but other agencies have become practical options: Japan's PMDA is open to global assets, the UK MHRA now clears clinical trial applications faster than the FDA, and the EMA has introduced the EU-CTR framework and a FAST-EU pilot. The approach reduces dependence on any single regulator and can shorten the time to patient access across markets.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biospace.comBiotechs going to market alone must learn to go global
After the funding rebound, biotechs choosing to bring products to market independently must plan for parallel global submissions from day one of development, to reduce dependence on any single regulator and speed patient access. The FDA remains the regulatory anchor; Japan's PMDA is open to global assets, the UK MHRA's clinical trial application timelines are now shorter than the FDA's, and the EMA has launched EU-CTR and the FAST-EU pilot.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 28 13:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.